Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny drug particles aim to target tough breast, ovarian, and endometrial cancers

NCT ID NCT06738966

Recruiting now Disease control Sponsor: Shanghai Best-Link Bioscience, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing an experimental drug called BL0175, a nano-medicine designed to deliver treatment directly into tumors. It is for postmenopausal women with advanced or metastatic hormone-receptor-positive breast, ovarian, or endometrial cancer that has progressed after hormone therapy. The main goals are to check the drug's safety, find the highest safe dose, and see if it can slow cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BL0175 (a nano-medicine that delivers an estrogen receptor down regulator directly into tumors)
What this could lead to
If it works, this could point toward a new treatment option for hormone-receptor-positive cancers that have stopped responding to standard hormone therapy.
What could go wrong
This is a very early Phase 1 trial with only 9 participants, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm endometrial cancer endometrial carcinoma endometrium neoplasm hormone receptor-positive breast cancer ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER ENDOMETRIAL CANCER OVARIAN CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Jinan Central Hospital

    RECRUITING

    Jinan, Shandong, 250000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Hospital of Jilin University

    RECRUITING

    Changchun, Jilin, 130000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.